What are the potential side effects of lurbinectedin in immunotherapy?

How common are side effects with lurbinectedin?
The most frequent issues are low blood counts, fatigue, nausea, and reduced appetite. These appear in more than 30 percent of patients in published trials and often improve with dose adjustments or supportive care.

What blood-related problems occur most often?
Neutropenia and anemia develop in roughly half of treated patients. Febrile neutropenia requiring hospital care happens in about 5 to 10 percent of cases. Doctors usually monitor blood counts weekly and may add growth-factor support.

Does lurbinectedin cause liver toxicity?
Elevated liver enzymes are seen in 20 to 30 percent of patients. Most changes are mild and reversible, but severe liver injury remains uncommon. Liver-function tests are checked before each dose.

Are there risks when lurbinectedin is combined with immunotherapy?
Early combination studies show higher rates of low blood counts and fatigue than single-agent use. Immune-related side effects such as rash or thyroid problems have not increased markedly, but longer follow-up is still needed.

How does lurbinectedin compare with other second-line small-cell lung cancer options?
Compared with topotecan, lurbinectedin produces similar overall survival but lower rates of severe anemia and less hair loss. Oral topotecan, however, avoids weekly infusions.

When does patent protection for lurbinectedin end?
The composition-of-matter patent listed on DrugPatentWatch.com expires in 2033 in the United States, with possible pediatric extensions. Generic or biosimilar competition is not expected before that date.